Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PMID: 33734374
2021
The Journal of antimicrobial chemotherapy
Abstract: In December 2019, the remaining three subjects carrying M184V/I in pDNA maintained suppressed viraemia, and two still used emtricitabine in ART.
Abstract: METHODS: We included vertically HIV-infected youths/young adults aged >=10 years in the Madrid Cohort of HIV-1 Infected Children and Adolescents, exposed to lamivudine and/or emtricitabine, with M184V/I and/or K65R/E/N in historic plasma samples, on antiretroviral therapy (ART), virologically suppressed (HIV-1 RNA <50 copies/mL), and with available PBMCs in the Spanish HIV BioBank.
Abstract: Nine (75%) youths did not present M184V/I in pDNA after at least 1 year of viral suppression.
Abstract: OBJECTIVES: We analysed the prevalence of PMID: 33788308
2021
Journal of medical virology
Abstract: The most common primary mutations found were M184V (29.5%), K103N (25%), M41L (9.8%), T215Y (8.3%), and G190A (8.3%).
A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells.
Abstract: In this study, we established such an assay and validated it using 346 primary HIV-1 isolates from patients enrolled in the Zurich Primary HIV Infection study (ZPHI) and two control viruses, HIV-1 JR-CSFWT and HIV-1 JR-CSFK65R_M184V.
Result: Furthermore, HIV-1 JR-CSFWT replicates at a higher efficiency when compared to the replication kinetics of HIV-1 JR-CSFK65R_M184V (Figure 3D,E).
Result: HIV-1 JR-CSFK65R_M184V replicated more than 3-logs lower than HIV-1 JR-CSFWT.
Result: Interestingly, one primary HIV-1 isolate had a lower replication capacity than HIV-1 JR-CSFK65R_M184V.
Result: It has been previously shown that the K65R mutation reduces replication capacity up to 55% compared to the wildtype virus, but when paired with the
Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients.
PMID: 33855355
2021
The Journal of antimicrobial chemotherapy
Abstract: Resuming the same 2-DR 7 days a week led to viral resuppression in three patients, whereas the M184V mutation emerged in one patient, leading to ART modification.
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
Abstract: CONCLUSIONS: In this real-world cohort, the majority of whom had virus with the M184V/I and >= 1 additional NA mutation, switching to DTG functional mono-or dual therapy with a non-cytosine NA resulted in persistent HIV-1 RNA >= 50 copies/mL in 18%.
Abstract: Historical genotypes indicated that all had an M184V/I, and 23 (59%) had an M184V/I and >= 1 additional NA mutation.
Introduction: In both the GEMINI and TANGO studies, patients with baseline nucleoside reverse transcriptase inhibitor (NRTI) resistance include those with M184V/I and integrase strand transfer inhibitor (INSTI) resistance were excluded.
Introduction: Prior reports have demonstrated a h
Distribution characteristics of drug resistance mutations of HIV CRF01_AE, CRF07_BC and CRF08_BC from patients under ART in Ganzhou, China.
PMID: 34402512
2021
The Journal of antimicrobial chemotherapy
Abstract: The most common DRMs of these three subtypes were K103N and M184V, while the mutation frequencies of M41L, D67N, K70R, K101E, V106M, Y181C, K219E, H221Y and N348I were obviously different among subtypes.
Transmitted drug resistance and transmission clusters among HIV-1 treatment-naive patients in Guangdong, China: a cross-sectional study.
Result: K103N (0.42%, 10/2368), Y181C (0.21%, 5/2368), and G190A (0.21%, 5/2368) were the most common NRTI-associated mutations, and M184V (0.21%, 5/2368), L210W (0.21%, 5/2368), and T215S (0.13%, 3/2368) were the most common NNRTI-associated mutations.
Discussion: The most frequent NRTI-associated mutations in our study were M184V and L210W, while they are M41L and D67G in Southwest China and T215C/D in Iceland and the south-central United States.
Phylogenetic and Drug-Resistance Analysis of HIV-1 Sequences From an Extensive Paediatric HIV-1 Outbreak in Larkana, Pakistan.
Result: The DRM RT:M184V was found in two sequences - both in cluster_CRF02_AG_1.
Table: M184V
Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding.
PMID: 34446677
2021
Journal of acquired immune deficiency syndromes (1999)
Abstract: We did not observe differences in probability of VF in people living with HIV with an M184V resistance mutation (P = 0.689); however, in a deeper analysis, M184V mutation was a predictor of VF (P = 0.038) in patients with time of virological suppression <88 months.
Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.
PMID: 34516245
2021
Antimicrobial agents and chemotherapy
Abstract: A114S/M184V exhibited higher EFdA resistance (~24-fold) than either M184V (~8-fold) or A114S alone (~2-fold).
Abstract: A novel EFdA resistance mutational pattern that included A114S was identified in the background of M184V.
Abstract: Biochemical experiments confirmed decreases in the enzymatic efficiency (kcat/Km) of WT versus A114S (2.1-fold) and A114S/M184V/A502V (6.5-fold) RTs, with no effect of A502V on enzymatic efficiency or specific infectivity.
Abstract: Regardless of the starting viral sequence, all selected EFdA-resistant variants i
HIV mutation literature information.
PMID: 
2021
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT